GLP-1 Weight Loss Medications: Expert Guide 2024

Medically reviewed by the Vea Health Clinical Team

TL;DR: GLP-1 weight loss medications like semaglutide have demonstrated average weight reductions of 15-20% in clinical trials, according to research published in The New England Journal of Medicine. These physician-led protocols work by regulating appetite and blood sugar management, offering a personalized approach for adults struggling with obesity.

GLP-1 weight loss medications represent one of the most significant advances in managing obesity over the past decade. These protocols offer more than temporary fixes. They work with your body's natural systems to support sustainable change.

If you've tried traditional approaches without lasting success, you're not alone. Many patients find that evidence-based protocols provide the support their journey needs.

What Are GLP-1 Weight Loss Medications?

GLP-1 receptor agonists are a class of medications that mimic a naturally occurring hormone called glucagon-like peptide-1. This hormone plays a key role in regulating appetite, blood sugar levels, and how quickly your stomach empties after eating. The medications work by activating specific receptors in your brain and digestive system that control hunger signals and food intake.

Your body produces GLP-1 naturally when you eat. But it breaks down quickly, within minutes. The medications used in weight management protocols are designed to last much longer in your system. This extended activity provides consistent appetite regulation throughout the day and week, depending on the specific protocol.

Common GLP-1 medications include semaglutide and tirzepatide. Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide works on both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. Both have shown significant results in clinical research. The choice between options depends on your individual health profile and goals.

At Vea Health, physicians evaluate your complete health picture before recommending a protocol. This includes your medical history, current medications, and specific objectives for your journey.

How Effective Are GLP-1 Medications for Weight Loss?

Clinical trials show impressive results for GLP-1 protocols in weight management. A 2021 study by Wilding and colleagues in The New England Journal of Medicine found that adults taking once-weekly semaglutide 2.4 mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% in the placebo group. Nearly one-third of participants lost 20% or more of their starting weight, a result rarely seen with lifestyle changes alone.

A systematic review and meta-analysis published in 2022 confirmed these findings across multiple studies. Researchers analyzed data from patients without diabetes and found consistent weight reduction outcomes. The evidence supports the use of semaglutide as an effective option for obesity management when combined with lifestyle modifications.

But what about maintaining that weight loss? Research addresses this crucial question. The STEP 4 trial by Rubino and colleagues examined what happens when patients continue versus stop their protocol. After an initial 20-week run-in period where all participants received semaglutide, those who continued the medication maintained their weight loss and lost additional weight. Those switched to placebo regained much of what they'd lost. This suggests that ongoing protocol adherence supports sustained results.

14.9% average weight reduction

Adults taking semaglutide 2.4 mg weekly over 68 weeks, according to Wilding et al. in The New England Journal of Medicine (2021).

Patients have reported improvements beyond the scale as well. Many notice changes in how they think about food, reduced cravings, and feeling satisfied with smaller portions. These subjective experiences align with the medication's mechanism of action on appetite centers in the brain.

Comparing Semaglutide and Other GLP-1 Options

Different GLP-1 medications offer varying levels of effectiveness and dosing schedules. Understanding these differences helps you and your physician choose the most appropriate protocol for your needs. Research comparing these options provides valuable insights into their relative benefits.

The STEP 8 trial by Rubino and colleagues directly compared once-weekly semaglutide 2.4 mg with once-daily liraglutide 3.0 mg, both established GLP-1 medications for weight management. After 68 weeks, participants taking semaglutide achieved a mean weight loss of 15.8% compared to 6.4% with liraglutide. Both groups received counseling on diet and physical activity. This head-to-head comparison demonstrates meaningful differences in efficacy between GLP-1 options, even within the same medication class.

Tirzepatide represents a newer approach with dual receptor activity. A 2021 study by Frías and colleagues in The New England Journal of Medicine compared tirzepatide with semaglutide in patients with type 2 diabetes. While this study focused on diabetes management rather than weight loss specifically, tirzepatide showed greater reductions in both blood sugar levels and body weight across all dose levels tested. This dual-agonist approach may offer advantages for certain patients, though more research in non-diabetic obesity is ongoing.

So which option is right for you? That depends on several factors. Your physician will consider your medical history, any existing conditions like diabetes, your response to previous treatments, and practical considerations like dosing frequency. Some patients prefer once-weekly injections for convenience. Others may benefit from the dual mechanism of tirzepatide. There's no single best choice for everyone.

It's worth noting that individual responses vary. Some patients respond exceptionally well to one medication but may need to switch if they experience side effects or don't see expected results. This is why physician-led protocols at Vea Health include ongoing monitoring and adjustment.

What About Side Effects?

Clinical studies indicate that gastrointestinal effects are the most common side effects reported with GLP-1 medications. These typically include nausea, diarrhea, constipation, and abdominal discomfort. In the STEP 1 trial, these effects were generally mild to moderate and decreased over time as patients adjusted to the medication.

Most side effects occur during the initial weeks or when increasing doses. That's why protocols typically start at lower doses and gradually increase. This titration approach helps your body adapt while minimizing discomfort.

Serious side effects are rare but possible. Your physician will discuss your complete risk profile during consultation. They'll also monitor you throughout your journey to catch any concerns early.

What Can You Expect During Your Journey?

Starting a GLP-1 protocol involves several stages, from initial consultation through ongoing management. Understanding this timeline helps set realistic expectations and prepares you for the process ahead. Most patients begin noticing changes within the first few weeks, though individual experiences vary considerably.

Your journey typically starts with a comprehensive health evaluation. A physician reviews your medical history, current medications, and weight loss goals. They'll assess whether you're a good candidate based on factors like BMI, existing health conditions, and previous weight management attempts. If a GLP-1 protocol is appropriate, they'll create a personalized plan tailored to your needs.

The first month focuses on initiation and adjustment. You'll start at a lower dose to help your body adapt. Many patients report reduced appetite within the first week or two. Some notice they feel full faster during meals or think about food less frequently between meals. Weight changes during this initial phase vary, but modest reductions are common even at starter doses.

Months two through four involve gradual dose increases. Your physician will adjust your protocol based on how you're responding and tolerating the medication. This is when many patients see more significant weight changes. According to the STEP 3 trial by Wadden and colleagues, participants receiving semaglutide alongside intensive behavioral therapy achieved substantial weight loss by the 12-week mark, with continued improvement through 68 weeks.

The maintenance phase begins once you reach your target dose and start seeing steady progress. This doesn't mean the work is done. Research from the STEP 4 trial clearly shows that continued protocol adherence is important for maintaining results. Your physician will schedule regular check-ins to monitor your progress, adjust your protocol if needed, and address any concerns that arise.

Lifestyle Factors Still Matter

GLP-1 medications are prescribed as an adjunct to lifestyle modifications, not a replacement for them. The most successful outcomes in clinical trials occurred when patients combined medication with changes to eating patterns and physical activity. Think of the medication as a tool that makes those lifestyle changes more achievable and sustainable.

You don't need to follow a restrictive diet plan. But you'll probably find that the medication naturally guides you toward healthier choices. When you feel satisfied with less food and don't experience intense cravings, it becomes easier to make decisions that support your goals.

Who Is a Good Candidate for GLP-1 Protocols?

Clinical guidelines and research studies help define who may benefit most from GLP-1 weight loss medications. These protocols aren't appropriate for everyone, and careful screening ensures they're prescribed to patients who'll benefit while minimizing risks. Physicians evaluate multiple factors when determining candidacy for these evidence-based approaches.

Most clinical trials enrolled adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related health condition. These thresholds reflect the populations studied in research like the STEP trials. If you meet these criteria and haven't achieved lasting results with diet and exercise alone, you may be a candidate. Your physician will assess your individual situation rather than relying solely on BMI numbers.

Certain medical conditions may make GLP-1 protocols particularly beneficial. Research by Bliddal and colleagues published in 2024 examined semaglutide in people with both obesity and knee osteoarthritis. The study found that weight reduction led to significant improvements in pain and physical function scores. This suggests that patients with weight-related joint problems might see benefits beyond weight loss alone. Similarly, research on tirzepatide by Packer and colleagues in 2025 explored effects in patients with heart failure and obesity, finding improvements in heart failure outcomes alongside weight reduction.

However, some people shouldn't use GLP-1 medications. Those with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not take these medications due to safety concerns identified in animal studies. Pregnancy and breastfeeding are also contraindications. Your physician will review your complete medical history to identify any factors that would make these protocols inappropriate for you.

Age considerations matter too. Most studies focused on adults, though research by Weghuber and colleagues examined semaglutide in adolescents aged 12 to 18 with obesity. Results showed significant weight reduction compared to placebo, suggesting these protocols may help younger patients when appropriate. Older adults can also benefit, though physicians consider additional factors like other medications and age-related health conditions.

The best candidates are those ready to commit to the full journey. These protocols work best when combined with lifestyle changes and ongoing medical supervision. If you're looking for a quick fix or aren't willing to make other changes, these medications probably won't deliver the results you want.

At Vea Health, our physicians take a personalized approach to determining candidacy. They don't just check boxes on eligibility criteria. They consider your complete health picture, your goals, and what's realistic for your life. This ensures that if you start a protocol, it's truly the right choice for you.

Ready to explore your options?

Our physicians can help determine if a GLP-1 protocol aligns with your health goals. Start your consultation to learn more about personalized approaches to weight management.

What About Cost and Access?

Access to GLP-1 medications varies based on insurance coverage, pharmacy availability, and whether you're prescribed brand-name or compounded versions. Many insurance plans have specific requirements for coverage, such as documented previous weight loss attempts or certain BMI thresholds. Telehealth providers like Vea Health can help navigate these considerations and discuss options that fit your situation.

Frequently Asked Questions

How long does it take to see results with GLP-1 weight loss medications?

Most patients begin noticing appetite changes within the first one to two weeks of starting their protocol. Measurable weight changes typically become apparent within the first month, with more significant reductions accumulating over several months. According to the STEP trials, peak results occurred around 60-68 weeks of consistent use, though individual timelines vary considerably.

Can you stop taking GLP-1 medications once you reach your goal weight?

Research from the STEP 4 trial by Rubino and colleagues found that patients who discontinued semaglutide after reaching their target weight regained a significant portion of what they'd lost, while those who continued maintained their results. This suggests that ongoing protocol adherence may be necessary for sustained weight management. Your physician will discuss long-term strategies tailored to your situation.

Do GLP-1 medications work for everyone?

Individual responses vary. While clinical trials show average weight reductions of 15-20%, some patients lose more and others less. Factors affecting response include adherence to the protocol, concurrent lifestyle changes, metabolic factors, and individual biology. If you don't respond adequately to one GLP-1 option, your physician may adjust the dose or consider alternative approaches.

What's the difference between semaglutide and tirzepatide?

Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide activates both GLP-1 and GIP receptors. According to research by Frías and colleagues, tirzepatide showed greater weight reduction in head-to-head comparisons, though this was studied primarily in patients with type 2 diabetes. Both medications are administered as once-weekly injections and have shown significant efficacy in clinical trials.

Are GLP-1 weight loss medications safe long-term?

Clinical trials have followed patients for up to 68 weeks with generally favorable safety profiles. The most common side effects are gastrointestinal in nature and typically mild to moderate. Long-term safety beyond two years is still being studied as these medications are relatively new for weight management. Your physician will monitor you regularly to identify any concerns early and adjust your protocol as needed.

References

1. Wilding J et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. 2021. PMID: 33567185

2. Tan H et al. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. Journal of the ASEAN Federation of Endocrine Societies. 2022. PMID: 36578889

3. Frías J et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England Journal of Medicine. 2021. PMID: 34170647

4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID: 33755728

5. Davies M et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. PMID: 33667417

6. Bliddal H et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England Journal of Medicine. 2024. PMID: 39476339

7. Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity. The New England Journal of Medicine. 2022. PMID: 36322838

8. Packer M et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. The New England Journal of Medicine. 2025. PMID: 39555826

9. Rubino D et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022. PMID: 35015037

10. Wadden T et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021. PMID: 33625476

Source Studies:

• Once-Weekly Semaglutide in Adults with Overweight or Obesity. — The New England journal of medicine (2021)

• Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: ... — Journal of the ASEAN Federation of Endocrine Societies (2022)

• Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. — The New England journal of medicine (2021)

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

Treatments are prescribed at provider discretion. Individual results may vary.